1,721,087 research outputs found
Hospital antibiotic management in north-eastern Italy – result of the ABS aturity survey of the ABS International group
No full text
Phosphatase activity is a constant feature of all clinical isolates of all major species of the family Enterobacteriaceae.
No full textIn vitro susceptibility and tissue distribution of antibiotics: a computerized approach to the antibiogram interpretation
No full textForthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens
No full textMultidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA beta-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature
Hen-egg white lysozyme improves plaque formation of herpes and influenza viruses in agar solidified media
No full textIn vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern european hospital
No full textHen egg white lysozyme improves plaque formation in Herpes simplex and influenza viruses in agar solidified media
No full textEvaluation of ceftriaxone and other antibiotics against E. coli, P. aeruginosa and Streptococcus pneumoniae under in vitro conditions simulationg those of serious infections.
No full text- …
